Clinical Observation on Orthopedics No.1 Prescription Combined with Celecoxib in Treating Knee Osteoarthritis with Middle Stage of Cold-dampness Syndrome
10.13422/j.cnki.syfjx.20202330
- VernacularTitle:骨伤1号方联合塞来昔布治疗寒湿痹阻证膝骨关节炎的临床观察
- Author:
Ya-qi ZHANG
1
;
Zi-yi ZHAO
1
;
Ling-ling QIN
2
;
Cheng-fei ZHANG
3
;
Yi ZHAO
1
;
Jing-pei REN
1
;
Ji-zhou YANG
1
;
Xiao-hong MU
1
Author Information
1. Dongzhimen Hospital，Beijing University of Chinese Medicine， Beijing 100700，China
2. Beijing University of Chinese Medicine， Beijing 100029，China
3. Dongfang Hospital，Beijing University of Chinese Medicine， Beijing 100078， China
- Publication Type:Research Article
- Keywords:
knee osteoarthritis;
cold-dampness syndrome;
orthopedics No.1 prescription;
cytokines
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2021;27(2):93-97
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the clinical efficacy of orthopedics No.1 prescription combined with celecoxib in the treatment of knee osteoarthritis （KOA） with middle stage of cold-dampness syndrome and investigate its effect on serum cytokines levels. Method:The 72 patients were randomly divided into control group and observation group， with 36 cases each. Patients in both groups were given basic treatment with oral celecoxib capsules （0.2 g/ time， 1 time/day）. On the basis of western medicine treatment， patients in observation group were treated with orthopedics No.1 prescription decoction-free granules by fumigation， 1 bag/time， 1 time/day， 5 times/week. Both groups received treatment for 4 weeks. The visual analog pain score （VAS）， American knee society knee score （KSS）， serum interleukin-1β （IL-1β）， tumor necrosis factor-α （TNF-α）， and transforming growth factor-β1 （TGF-β1） levels were observed before and after treatment， and their clinical efficacy was evaluated. Result:After treatment， VAS score significantly decreased in both groups （P<0.01）， and KSS score significantly increased （P<0.01）， with better clinical effect in observation group. After treatment， serum IL-1β and TNF-α levels decreased significantly in both groups （P<0.01）， and the levels in observation group were lower than those in control group after treatment （P<0.05）. TGF-β1 content was significantly higher than that before treatment in two groups （P<0.01）. Conclusion:Orthopedics No.1 prescription combined with celecoxib for the treatment of KOA with middle stage of cold-dampness syndrome can effectively relieve the clinical symptoms of patients with KOA， improve joint function， improve quality of life， reduce the contents of inflammatory factors IL-1β and TNF-α in serum， and increase the expression of TGF-β1 level.
